Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Award

Photo Pending

Vijay Sharma, Ph.D.

Washington University
St. Louis, MO

Title: Imaging PGP-Mediated Transport in Alzheimer's Disease
Non-Technical Title: Improving imaging tools for diagnosis of AD

Duration: April 1, 2007 - March 31, 2010
Award Type: Pilot
Award Amount: $150,000


Summary:

We propose to evaluate the potential of lead Pgp-targeted agent to act as noninvasive probe to detect those defects in brains of mouse models via PET imaging. Additionally, our strategy is amenable to kit formulation with potential for widespread deployment of a test for managing AD.

Details:

Alzheimer’s Disease (AD) patients demonstrate loss of neurons in regions of the brain responsible for learning and memory (hippocampus) and the presence of distinct protein aggregates, commonly known as amyloid plaques. Emerging new models for occurrence of the disease indicate that pathways in disease progression are likely mediated by transporters prevalent in the brain. Among these transporters, P-glycoprotein (Pgp) known to block penetration of numerous drugs or cytotoxins into brain may likely be involved in buildup of amyloid plaques within the brains of AD patients. We hypothesize that natural function involving Pgp mediating efflux of amyloid plaques out of the CNS may likely be compromised in diseased patients compared with the normal ones and the process initiates prior to appearance of symptoms for the disease. Thus, ultrasensitive-diagnostic agents capable of evaluating that novel risk factor in terms of individual variations in Pgp transport would likely assist in patient stratification and guide therapeutic choices. Herein, we propose to evaluate the potential of lead Pgp-targeted agent to act as noninvasive probe to detect those defects in brains of mouse models via PET imaging. Additionally, our strategy is amenable to kit formulation with potential for widespread deployment of a test for managing AD.